Clinical Trial Update: Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating doxazosin GI therapeutic system on ambulatory blood pressure and cardiovascular risk factors in uncontrolled hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Doxazosin GI therapeutic system (doxazosin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Hypertension | Phase 4 | Status: COMPLETED